Turkish private equity group invests $39M to support Harvard researcher’s next-gen obesity antibodies

Harvard researcher Gökhan Hotamışlıgil has secured $39 million from Turkish investment group İş Private Equity to fund his lab's research on antibodies for obesity and metabolic diseases, mitigating the impact of recent federal funding cuts. The investment will support preclinical characterization of antibodies targeting aP2, a hormone linked to metabolic pathologies, with the aim of developing potential therapies through a newly established U.S.-based biotech venture called Enlila. This funding model reflects a broader trend at Harvard, where faculty are being encouraged to pursue industry partnerships amid declining federal research grants, though Hotamışlıgil notes that industry support cannot fully replace federal funding for basic science.

Analysis

Harvard University researcher Gökhan Hotamışlıgil has secured approximately $39 million from İş Private Equity, a subsidiary of Istanbul-based İşbank Group (ISBK), to fund ten years of research into novel antibodies for obesity and metabolic diseases, a significant development as Harvard faces extensive federal funding cuts attributed to the Trump administration. This investment will support preclinical characterization of antibodies targeting the FABP4 (aP2) hormone, which showed promise in 2015 by reducing blood glucose and fat mass in obese mice. A new U.S. biotech, Enlila, is planned to launch and may license these antibodies for clinical development. İşbank CEO Hakan Aran, in a June 16 release, emphasized the goal of transforming scientific discovery into therapy. This private funding initiative aligns with guidance from Harvard Chan School of Public Health Dean Andrea Baccarelli, who, in a June 11 email, urged faculty to pursue 'direct and purposeful industry engagement' amid federal grant reductions, exemplified by Dr. Hotamışlıgil's own canceled NIH training grant and stalled research grant. Dr. Hotamışlıgil noted that while industry support is vital, particularly for mature research like his (the aP2 hormone was discovered 20 years ago), it cannot fully replace federal funding for foundational science.

Key Decisions for Investors

• For investors in İşbank (ISBK), this $39 million commitment via its private equity arm, while modest in overall financial scale, reflects a strategic foray into long-term biotech innovation and should be monitored as part of its alternative investment strategy.
• Biotechnology sector investors should note the emergence of Enlila and its focus on aP2 antibodies for metabolic diseases as a potential future player, warranting inclusion on watchlists for preclinical and clinical development milestones.
• Institutional investors and venture capital firms should consider the increasing trend of private funding for academic research, exemplified by this partnership, as an avenue for early access to scientific breakthroughs, particularly in environments with reduced public R&D expenditure.
• Investors should remain cognizant of the extended development timelines and inherent risks associated with early-stage biopharmaceutical research, viewing this specific funding as a long-term catalyst rather than an immediate market-moving event for broader indices.